UNICALIQ L/N（ユニカリック輸液）-为静脉营养，电解质，能量和氨基酸的补充剂
治疗类别名称
高卡路里输液 糖，氨基酸，电解质溶液
欧洲商品名
UNICALIQ L
UNICALIQ N
薬効薬理
开腹执法大鼠，在第一天仅UNICALIQ L输注150kcal/kg/天，2天后，被静脉内施用UNICALIQ L输注在210kcal/kg/天至6天，稳定体重增加和表现出良好的正氮平衡，观察营养作用
剂量和给药方法
UNICALIQ L输液
该药物是在通过中央静脉输液治疗开始时，视情况的起始溶液或如果糖耐量糖耐量是未知的降低，或已在入侵或类似糖耐量下降，以限制葡萄糖我用作为维持溶液时有需要。
典型地，持续输注到中心静脉天2000ML超过24小时的成人。
此外，将根据年龄，症状调整，以重量计。
UNICALIQ N输液
通过中心静脉输液治疗的维护解决方案中使用。
典型地，持续输注到中心静脉天2000ML超过24小时的成人。
此外，将根据年龄，症状调整，以重量计。
包装规格
UNICALIQ L 输液：1,000毫升×10袋/箱
UNICALIQ N 输液：1,000毫升×10袋/箱
生产商：田边三菱制药
Efficiency classification name
Sugar for high-calorie infusion, amino acids, electrolyte solution
Brand Name
Yunikarikku L infusion (1000mL)
composition
Component-quantity> 1 bag 1000mL in
Active ingredient
L- isoleucine 2.13g
L- leucine 3.38g
Lysine malic acid 3.03g
(L- 1.99g as lysine)
L- methionine 1.23g
L- phenylalanine 1.93g
L- threonine 1.20g
L- tryptophan 0.40g
L- valine 2.25g
L- tyrosine 0.13g
L- arginine hydrochloride 3.35g
(2.77g as L- arginine)
L- histidine hydrochloride 1.59g
(1.18g as L- histidine)
L- alanine 2.15g
L- aspartic acid 0.13g
Glycine 1.38g
L- proline 1.73g
L- serine 1.05g
Glucose 125g
Potassium chloride 1.410g
Magnesium sulfate hydrate 0.616g
Magnesium chloride 0.102g
Calcium gluconate hydrate 1.345g
Potassium dihydrogen phosphate 1.100g
L- lactic acid sodium solution 7.840g
(3.920g as L- lactic acid sodium)
Zinc sulfate hydrate 5.75mg
Glacial acetic acid 0.601g
Total free amino acid 25.03g (2.50w / v%)
Branched-chain amino acids (BCAA) content of 31.00%
Essential amino acid / non-essential amino acid 1.38
Total nitrogen 3.89g
The total amount of heat 600kcal
Non-protein amount of heat 500kcal
Non-protein amount of heat / nitrogen 128
<Electrolytic mass>
Na + 40mEq
K + 27mEq
Ca2 + 6mEq
Mg2 + 6mEq
Cl- 55mEq
L-Malate2- 14mEq
L-Lactate- 35mEq
Acetate- 10mEq
Gluconate- 6mEq
P 250mg
Zn 20μmol
Contraindication
Patients with lactic acid blood disease
[There is a possibility that the lactic acid blood disease worsens. ]
Patients with hypernatremia
[There is a possibility that the high sodium blood disease worsens. ]
Patients with high crawl blood disease
[There is a possibility that the high crawl blood disease worsens. ]
Hyperkalemia, oliguria, Addison's disease, of azotemia patient
[There is a possibility that the high potassium blood disease, is exacerbated or induced. ]
Hyperphosphatemia, of hypoparathyroidism patients
[There is a possibility that the hyperphosphatemia, is exacerbated or induced. ]
Hypermagnesemia, patients with hypothyroidism
[There is a possibility that the high magnesium blood disease, is exacerbated or induced. ]
Patients with hypercalcemia
[There is a possibility that hypercalcemia is worsened. ]
Patients at risk of hepatic coma or hepatic coma
[There is a possibility that hepatic coma is exacerbated or induced. ]
Patients with severe renal failure
[There is a possibility that the high nitrogen blood disease is induced. ]
Patients with amino acid metabolic disorder
[There is a possibility that amino acid imbalance is promoted. ]
Efficacy or effect
Oral, enteral tube feeding is impossible or insufficient, moisture if you have no choice but to rely on through central venous nutrition, replenishment of electrolytes, calories and amino acids.
Yunikarikku L infusion:
The drug is at the start of through central venous infusion therapy, as a starting solution of the case or if the glucose tolerance glucose tolerance is unknown is reduced, or has decreased glucose tolerance in the invasion or the like, to limit the glucose It used as a maintenance solution when there is a need.
Typically, the sustained infusion into the central venous day 2000mL over 24 hours for adults.
In addition, it will be adjusted according to age, symptoms, by weight.
Yunikarikku N infusion:
The drug I use as a maintenance solution through central venous infusion therapy.
Typically, the sustained infusion into the central venous day 2000mL over 24 hours for adults.
In addition, it will be adjusted according to age, symptoms, by weight.
Because sometimes severe acidosis occurs, and a combination of vitamin B1 of the absolutely necessary amount (a guide more than one day 3mg) thing.
Careful administration
Patients with bacteremia
[Catheter may become a secondary infection foci, septic even there is a risk of septic shock. ]
Patients with dehydration
[There is a possibility that the dehydration is worsening. ]
Patients with renal failure based on renal disease
there is a possibility that [renal failure condition is worsening. ]
Patients with severe burns
High blood sugar is induced, there is a possibility that the dehydration symptoms worse. ]
Patients with renal failure without hyperkalemia
there is a possibility that [renal failure condition is worsening. ]
Patients with heart failure
[There is a possibility that heart failure is worsening. ]
Patient the amount of urine is reduced by obstructive uropathy
[Some water, is a possibility that the electrolyte and nitrogen metabolites accumulate. ]
Patients with diabetes
there is a possibility that the [high blood sugar, is exacerbated or induced. ]
Patients with diabetes insipidus
[Water, is a risk that the electrolyte abnormality induced. ]
Patients with a high degree of acidosis
[There is a possibility that the acidosis worsens. ]
Patients pancreatitis, 膵硬 keratosis, a pancreatic disorder of pancreatic tumor, etc.
there is a possibility that the [high blood sugar, is exacerbated or induced. ]
Clinically significant adverse reactions
acidosis
Sometimes severe acidosis appears (see section "Warning").
Hyperglycemia
Since this drug is a high concentration of glucose-containing preparation, excessive hyperglycemia, osmotic diuresis, because it may dry mouth appears, to take appropriate measures such as insulin administration in the case of such symptoms .
Pharmacology
To laparotomy enforcement rat, the first day only the Yunikarikku L infusion 150kcal / kg / day, 2 days later, where it was administered intravenously Yunikarikku N infusion in 210kcal / kg / day up to 6 days, steady weight gain and showed good positive nitrogen balance, trophic effects were observed. )
http://www.kegg.jp/medicus-bin/japic_med?japic_code=00060294